179686-66-9Relevant articles and documents
Identification and characterization of the first fragment hits for SETDB1 Tudor domain
Mader,Mendoza-Sanchez, Rodrigo,Iqbal, Aman,Dong, Aiping,Dobrovetsky,Corless, Victoria B.,Liew, Sean K.,Houliston, Scott R.,De Freitas, Renato Ferreira,Smil,Sena, Carlo C. Dela,Kennedy, Steven,Diaz, Diego B.,Wu, Hong,Dombrovski, Ludmila,Allali-Hassani, Abdellah,Min, Jinrong,Schapira, Matthieu,Vedadi, Masoud,Brown, Peter J.,Santhakumar, Vijayaratnam,Yudin, Andrei K.,Arrowsmith, Cheryl H.
, p. 3866 - 3878 (2019/07/23)
SET domain bifurcated protein 1 (SETDB1) is a human histone-lysine methyltransferase which is amplified in human cancers and was shown to be crucial in the growth of non-small and small cell lung carcinoma. In addition to its catalytic domain, SETDB1 harb
HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
-
Page/Page column 93, (2016/05/19)
The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Benzodiazepine derivatives
-
, (2008/06/13)
The present invention provides benzodiazepine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of inhibiting activated blood-coagulation factor X. These compounds are usable as agents for treating various diseases concerned with the activated blood-coagulation factor X.
